HPLC analysis of mycolic acids in evaluation of drug susceptibility of Mycobacterium tuberculosis strains - comparison with conventional methods

• Autorzy: Walkiewicz R. , Chazan R. , Grubek-Jaworska H.
• Języki publikacji: EN

Abstrakty

EN

The commonly used phenotypic tests of M. tuberculosis drug susceptibility evaluate drug effects on quantity of colony forming units (CFU) on solid media or CO2 secretion/O2 con-sumption by cultures in liquid media. These tests are not precise enough and need a long time for the growth of the bacilli, so new more accurate and rapid methods are highly needed. The aim of this study was to determine the utility of quantitative HPLC analysis of mycolic acids for drug susceptibility of M. tuberculosis. In 119/120 (99.16%) of the performed tests the HPLC methods showed excellent agreement with the conventional phenotypic tests. The quantitative HPLC analysis of mycolic acids is a fairly exact indicator of tubercle bacilli growth and may be used as a quick and reliable measure of their drug sensitivity.

Słowa kluczowe

EN

HPLC; mycolic acids; drug susceptibility; M. tuberculosis

PL

HPLC; kwas mykolowy; wrażliwość na lek; bakteria; prątek gruźlicy

• Wydawca: Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences ; Elsevier
• Czasopismo: Biocybernetics and Biomedical Engineering
• Rocznik: 2010
• Tom: Vol. 30, no. 2
• Strony: 3--14
• Opis fizyczny: Bibliogr. 28 poz., tab., wykr.

Twórcy

autor

Walkiewicz R.

autor

Chazan R.

autor

Grubek-Jaworska H.

• Departament of Internal Medicine, Pneumology and Allergology, Medical University of Warsaw, ul. S. Banacha 1a, 02-097 Warsaw,

Bibliografia

• 1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report 2008. World Health Organization Document, 2008, WHO/HTM/TB/2008.393.
• 2. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (WHO/TB/97.229). Geneva, World Health Organization Document, 1997.
• 3. World Health Organization. Anti-tuberculosis drug resistance in the world. Report No. 2: prevalence and trends. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (WHO/CDC/TB/2000.278). Geneva, World Health Organization Document, 2000.
• 4. World Health Organization. Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD. Global Project on Anti-Tuberculosis Drug Resistance Surveillance (WHO/CDC/TB/2004.343). Geneva, World Health Organization Document, 2004.
• 5. World Health Organization. Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance (WHO/HTM/TB/2008.394). Geneva, World Health Organization Document, 2008.
• 6. Drobniewski F.S., Rüsch-Gerdes S., Hoffner S.: Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1) − Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin. Microbiol. Infect 2007, 13, 1144-1156.
• 7. Drobniewski F., Nikolayevskyy V., Hoffner S. et al.: The added value of a European Union tuberculosis reference laboratory network-analysis of the national reference laboratory activities. Eurosurveillance 2008, 13, Issue 11, 13 March 2008.
• 8. Palek L., Dvorák J., Svobodová M. et al.: Synthesis, antimycobacterial and antifungal evaluation of 3-arylaminopyrazine-2,5-dicarbonitriles. Arch. Pharm. (Weinheim) 2008, 341, 61-65.
• 9. Sharma A., Sharma S., Khuller G.K., Kanwar A.J.: In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int. J. Antimicrob. Agents. 2009, 34, 226-230.
• 10. Kim B.J., Lee K.H., Park B.N. et al.: Detection of rifampicin-resistant Mycobacterium tuberculosis in sputa by nested PCR-linked single-strand conformation polymorphism and DNA sequencing. J. Clin. Microbiol. 2001, 39, 2610-2617.
• 11. Van Der Zanden A.G., Te Koppele-Vize E.M. et al.: Use of DNA extracts from Ziehl-Neelsen-stained slides from molecular detection of rifampin resistance and spoligotyping of Mycobacterium tuberculosis. J. Clin. Microbiol. 2003, 41, 1101-1108.
• 12. Sam I.-C., Drobniewski F., More P., Kemp M., Brown T.: Mycobacterium Tuberculosis and Rifampicin Resistance, United Kingdom. Emerg. Infect Dis. 2006, 12, 752-759.
• 13. O'Riordan P., Schwab U., Logan S. et al.: Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PloS ONE. 2008, 3, 1-7.
• 14. Hillemann D., Rüsch-Gerdes S., Richter E.: Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2007, 45, 2635-2640.
• 15. Hillemann D., Rüsch-Gerdes S., Richter E.: Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2009, 47, 1767-1772.
• 16. Butler W.R., Ahearn D.G., Kilburn J.O.: High-performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Nocardia, Rhodococcus, and Mycobacterium species. J. Clin. Microbiol. 1986, 23, 182-185.
• 17. Butler W.R., Floyd M.M., Silcox V. et al.: Standardized method for HPLC identification of mycobacteria. HPLC users group in cooperation with Centers for Disease Control and Prevention. Atlanta: U.S. Public Health Service, CDC; 1996.
• 18. Safianowska A., Walkiewicz R., Grubek-Jaworska H. et al.: Abstract [Mycolic acids analysis from various species mycobacterium by high pressure liquid chromatography (HPLC)] (in Polish). Pneumonol. Alergol. Pol. 2002, 70, 130-138.
• 19. Walkiewicz R., Safianowska A., Grubek-Jaworska H. et al.: Use of mycolic acids analysis in diagnosis of tuberculosis and mycobacteriosis--three-year experience (Abstract) (in Polish) Pneumonol. Alergol .Pol. 2002, 70, 444-449.
• 20. Strong B.E., Kubica G.P.: Isolation and identification of Mycobacterium tuberculosis: A gide for the level lII laboratory. Atlanta, Georgia: Centers for Disease Control, US Department of Health and Human Services; 1981, 118-126.
• 21. Adjers-Koskela K., Katila M.L.: Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J. Clin. Microbiol. 2003, 41, 1235-1239.
• 22. National Committee for Clinical Laboratory Standards: Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes. Approved standard M24-A. National Committee for Clinical Laboratory Standards, 2003, Wayne, PA.
• 23. Mitchison D.A.: Drug resistance in tuberculosis. Review. Eur. Respir. J. 2005, 25, 376-379.
• 24. Bemer P., Palicova F.R., Rusch-Gerdes S. Drugeon H.B., Pfyffer G.E.: Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 2002, 40, 150-154.
• 25. Garza-Gonzales E., Guerrero-Olazaran M., Tijerina-Menchaca R., Viader-Salvado J.M.: Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis. J. Clin. Microbiol. 1997, 35, 1287-1289.
• 26. Viader-Salvadó J.M., Garza-González E., Valdez-Leal R. et al.: Mycolic acid index susceptibility method for Mycobacterium tuberculosis. J. Clin. Microbiol. 2001, 39, 2642-2645.
• 27. Parrish N., Osterhout G., Dionne K. et al.: Rapid, standardized method for determination of Mycobacterium tuberculosis drug susceptibility by use of mycolic acid analysis. J. Clin. Microbiol. 2007, 45, 3915-3920.
• 28. Kim S.J: Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 2005, 25, 564-569.